PolyPhotonix, a bio-photonic research and development company, designs, develops and manufactures non-invasive photonic based medical devices. They have been researching causes and treatments of eye disease for over 6 years.
Diabetic Retinopathy is caused by changes in the blood vessels of the retina. New fragile blood vessels start to grow and often leak blood and fluid. 90% of people with Type 1 diabetes will develop Diabetic Retinopathy within 10 years. 67% of people with Type 2 diabetes will develop Diabetic Retinopathy within 10 years.
PolyPhotonix was new to working with the NHS. The company had developed a light therapy mask for the prevention andtreatment of diabetic retinopathy, a condition which costs the NHS more than £1 billion a year. Current treatment costs up to £10,000 per patient for each eye; the Polyphotonix sleep mask costs £250 for 12 weeks treatment.
PolyPhotonix needed help to find practitioners and patients for a clinical study into the efficacy of the Noctura 400 sleep mask, a revolutionary treatment for diabetic retinopathy and diabetic macular oedema (DMO).
What we did:
Whilst working as Commercial Director for the SW AHSN Paula Varndell-Dawes assisted Polyphotonix to recruit local sites for their clinical study into Noctura 400 treatment for Diabetic Retinopathy to demonstrate and evaluate the care pathway for NHS adoption (CANDLE).
Paula was able to help with:
Introduction to the local Ophthalmology community, their assessment of the CANDLE protocol, and buy-in.
Recruitment of local PI’s with R&D support to participate in CANDLE.
Local NIHR introduction to support the CANDLE study recruitment, leading to site support and monitoring for on-‐time performance.
Interface and complimenting alignment with other supporting AHSN’s